SGLT-2 inhibitors reduce cardiovascular risk among patients with chronic kidney disease

SGLT-2 inhibitors, a type of diabetes medicine, decreased cardiovascular risk among adults with chronic kidney disease, according to late-breaking research presented today at the American Heart Association’s Scientific Sessions 2022.

SGLT-2 inhibitors reduce cardiovascular risk among patients with chronic kidney disease

Rosuvastatin vastly superior to six common heart health supplements

Children exposed to air pollution in early years more likely to develop food allergies

Understanding the possible mechanisms of myocardial injury in patients with COVID-19

New data from the nationwide INSPIRE study shows Long COVID is not a singular condition

HER2-targeted antibody drug conjugate shows encouraging responses, long-lasting clinical benefit in several tumor types

Developmental exposure to PCBs blocks hearing recovery from acoustic trauma

Comments

Leave a reply Cancel reply

More in News

CDC reports an alarming rise in pediatric intracranial infections in the U.S.

Simple blood test for the diagnosis of Glut1 deficiency syndrome

Study pinpoints the exact location of atherosclerotic plaque rupture

Personalized, bi-sensory stimulation may be an effective treatment for tinnitus

Important

Tend to get sick when the air is dry? New research helps explain why

Children with asthma at risk for anxiety

Examining the causal mechanism behind rare hereditary diseases

Must Read

JPIDS supplement issue focuses on eliminating health disparities in pediatric infectious diseases

An overview of the anti-inflammatory effects of nuts

The Switch was made for gaming on the go — these are the best cases for the handheld console

Popular Posts

Pornhub traffic doubled in D.C. on Election Day

12 sex tips for disabled people and their partners

User Experience Signals: The Essential SEO Factors

Lunar eclipse November 8: How to watch the last ‘blood moon’ of 2022